Qualified kidney biomarkers and their potential significance in drug safety evaluation and prediction.

The kidney is one of the major organs drug toxicity may target. Some renal safety biomarkers have been proposed to measure kidney injury and function accordingly. Despite the widespread use for diagnosis and monitoring of renal injury and function for decades, serum creatinine and blood urea nitrogen are nonspecific biomarkers with insensitive and delayed response in the clinical setting. There is an urgent need to identify and qualify novel kidney safety biomarkers that would be used to detect and predict drug-induced nephrotoxicity in preclinical toxicological studies, clinical trials and patient care in sequence. To do that, eight novel renal safety biomarkers have been well characterized and qualified for preclinical drug safety screening, and their clinical bridging validation is underway as well. Of them, some are used to detect or predict proximal tubular injury, and others are used to diagnose and monitor glomerular damage. Thus, measurement of a panel of kidney safety biomarkers in parallel would help maximally capture all potential safety signals for a more informative decision to be made in drug research and development as well as for optimal selection of the drug and its dose in clinical practice. Published by Elsevier Inc.

Citation

Hong-Guang Xie, Shu-Kui Wang, Chang-Chun Cao, Ernie Harpur. Qualified kidney biomarkers and their potential significance in drug safety evaluation and prediction. Pharmacology & therapeutics. 2013 Jan;137(1):100-7

Mesh Tags

Substances

PMID: 23017937

search → result